PCR Technology Market Research Report Information By Product (Reagents & Consumables, Instruments, Software & services), By Technique (Conventional PCR, Real-Time PCR, Digital PCR, Reverse Transcription PCR, Hot-start PCR, Multiplex PCR and Others), By End User (Hospitals and Diagnostic Centers, healthcare industry, Academia & Government Organizations, Pharma-Biotech Companies, Applied Industries and Others) And By Region (North America, Europe, Asia-Pacific, And The Rest Of The World) –Market Forecast Till 2034

PCR Technology Market Overview

As per MRFR analysis, the PCR Technology Market Size was estimated at 16.21 (USD Billion) in 2024. The PCR Technology Market Industry is expected to grow from 17.54 (USD Billion) in 2025 to 35.67 (USD Billion) till 2034, at a CAGR (growth rate) is expected to be around 8.20% during the forecast period (2025 - 2034). Increased demand for fast and precise diagnostic tools in diverse industries is the key market booster enhancing market growth.

Source: The Primary Research, Secondary Research, MRFR Database and Analyst Review

In March 2022, Stilla signed an agreement with 12 distributors across EMEA. The agreement allows for distribution rights of all of Stilla’s products, including Naica System (with six colors).

In April 2022, Stilla and Promega Corporation entered into a co-marketing partnership to deliver complete digital PCR workflow solution that ensures the optimized workflow for a wide range of applications such as liquid biopsy, sentinel pathogen testing, infectious disease assay, overall cancer research and drug discovery.

Bio-Rad Laboratories Inc. acquired Dropworks Inc., a development stage company developing a digital PCR product, in October 2021; the aim is to increase and complement the life science products of this strategy.

September 2021 witnessed Thermo Fisher Scientific launching Applied Biosystems QuantStudio Absolute Q Digital PCR System, which was designed as the first fully integrated digital Polymerase Chain Reaction (dPCR) system that can provide highly accurate and repeatable results.

PathStore announced the introduction of the COVID-19 RT-PCR test at the lowest price compared to others in India in July 2021. This rapid test is intended to maximize COVID-19 diagnoses by ensuring immediate treatment.

Just like in April 2021 when Centene partnered with Quest Diagnostics to drive real-time reverse transcription polymerase chain reaction (RRT-PCR) COVID-19 tests throughout America. In relation to that, Quest diagnostics heavily relied on its laboratory network for conducting COVID-19 tests. The kit was qualified by Federally Qualified Health Centers during the COVID-19 pandemic.

For example, in May 2021, Cipla Ltd launched ‘ViraGen,’ a polymerase chain reaction (COVID-19 Rt-PCR) test for COVID-19 with Ubio Biotechnology Systems Pvt Ltd., India. ViraGen is a real time detection kit approved by ICMR (Indian Council of Medical Research) based on PCR technology. This test is designed for the qualitative detection of nucleic acid from SARS-CoV-2 in the upper and lower respiratory specimens of individuals suspected of COVID-19.

PCR Technology Market Trends

• 
  

  Growing adoption of digital PCR techniques is driving the market growth

  
  

Market CAGR for polymerase chain reaction (PCR) technology is being driven by the adoption of digital PCR techniques, revolutionizing molecular diagnostics, research, and various other applications. Digital PCR represents a paradigm shift from traditional real-time PCR methods by offering enhanced precision, sensitivity, and quantification capabilities, thereby addressing limitations associated with conventional PCR assays.

Digital PCR offers several advantages over traditional PCR methods, making it an attractive option for a broader range of applications. One of the key benefits of dPCR is its ability to provide absolute quantification of nucleic acids without the need for standard curves, making it more robust and accurate for quantifying target DNA or RNA molecules. This capability is mainly valuable in applications where precise quantification is essential, such as in the detection and monitoring of viral load in infectious diseases like HIV or hepatitis, where accurate measurement of viral RNA levels is crucial for disease management and treatment decision-making. Moreover, digital PCR enables the detection of rare mutations or low-abundance targets with unparalleled sensitivity, surpassing the limitations of traditional PCR methods. This high sensitivity makes dPCR particularly valuable in applications such as cancer diagnostics and liquid biopsy, where the detection of minimal residual disease or circulating tumor DNA at very low concentrations is critical for early detection, prognosis, and monitoring of treatment response. Additionally, the ability of digital PCR to accurately quantify nucleic acids in complex sample matrices, such as blood, tissue, or environmental samples, further expands its utility in various research and diagnostic settings.

Furthermore, the increasing automation and scalability of digital PCR platforms have made them more accessible and cost-effective, driving their adoption across a broader range of laboratories and research facilities. Automation streamlines the workflow, reduces hands-on time, and minimizes variability, thereby improving efficiency and reproducibility. Additionally, the scalability of digital PCR platforms allows for high-throughput analysis, making them suitable for applications requiring large sample volumes or multiplexed assays, such as population-scale genetic studies or high-throughput screening for drug discovery.

The versatility of digital PCR technology extends beyond clinical diagnostics and research into fields such as agricultural biotechnology, food safety, environmental monitoring, and forensic analysis. In agriculture, digital PCR can be used for precise quantification of genetically modified organisms (GMOs) or pathogens in crops, ensuring food safety and regulatory compliance. In environmental monitoring, dPCR enables the accurate detection and quantification of microbial contaminants in water or soil samples, aiding in pollution assessment and remediation efforts. Additionally, digital PCR holds promise for forensic applications, such as DNA profiling and identification of human remains, where precise quantification and sensitivity are paramount. Thus, driving the PCR Technology Market revenue.

PCR Technology Market Segment Insights

Polymerase Chain Reaction (PCR) Technology Product Insights

The PCR Technology Market segmentation, based on product, includes Reagents & Consumables, Instruments and Software & services. In 2023, the reagents & consumables segment dominated the market as they are essential components required for every PCR reaction, including DNA polymerases, primers, nucleotides, buffers, and plastics. The consistent demand for these consumables across diverse research, clinical, and industrial applications ensures their significant market share and sustained revenue generation. Moreover, advancements in reagent formulations, packaging, and compatibility with various PCR platforms drive innovation and competition among manufacturers, further consolidating their influence in shaping the PCR technology market.

Figure 1: PCR Technology Market, by Product, 2023 & 2032 (USD Billion)

Source: The Primary Research, Secondary Research, MRFR Database and Analyst Review

Polymerase Chain Reaction (PCR) Technology Technique Insights

The PCR Technology Market segmentation, based on technique, includes Conventional PCR, Real-Time PCR, Hot-start PCR, Digital PCR, Reverse Transcription PCR, Multiplex PCR, and Others. In 2023, the real-time PCR category dominated the market due to its capability to provide rapid, quantitative analysis of nucleic acids in real time. Its high sensitivity, specificity, and broad applicability make it indispensable in various fields, including clinical diagnostics, research, and forensics. Real-time PCR's capability to monitor amplification continuously during the reaction enables precise quantification of target molecules, driving its widespread adoption and market dominance. Further, digital PCR is the fastest-growing category as it offers several benefits over traditional PCR techniques, including improved accuracy, higher sensitivity, and better precision.

Polymerase Chain Reaction (PCR) Technology End User Insights

The PCR Technology Market segmentation, based on end-users, includes Hospitals and Diagnostic Centers, Healthcare Industry, Academia & Government Organizations, Pharma-Biotech Companies, Applied Industries, and Others. In 2023, the hospitals and diagnostic centers category dominated the market due to their critical role in healthcare delivery and disease diagnosis. These institutions require reliable and high-throughput PCR systems for a wide range of applications, including infectious disease testing, genetic screening, and cancer diagnostics. Additionally, the increasing demand for rapid and accurate molecular testing in clinical settings further solidifies the position of hospitals and diagnostic centers as key drivers of growth in the PCR technology market. Further, the pharma-biotech companies are the fastest growing due to the rising development of new drugs and therapies that use PCR technology.

Polymerase Chain Reaction (PCR) Technology Regional Insights

The study provides market insights into North America, Europe, Asia-Pacific, and the Rest of the World by region. The North American PCR Technology Market area dominated this market because of the increasing demand for advanced molecular diagnostics in clinical settings and robust investments in biotechnology research and development by pharmaceutical and biotech companies. The favorable government initiatives and the presence of key market players contribute to the growth.

Further, the primary countries studied in the market report are the US, Canada, Germany, France, the UK, Italy, Spain, China, India, Australia, Japan, South Korea, and Brazil.

Figure 2: PCR TECHNOLOGY MARKET SHARE BY REGION 2023 (USD Billion)

Source: The Primary Research, Secondary Research, MRFR Database and Analyst Review

Europe PCR Technology Market accounts for the second largest market revenue share due to the growing prevalence of infectious diseases, advancements in molecular diagnostics, and the increasing adoption of personalized medicine. Further, the German PCR Technology Market had the largest market revenue share, and the UK PCR Technology Market was the fastest growing market in European region.

The Asia-Pacific PCR Technology Market is foreseen to rise at the fastest CAGR from 2025 to 2034. This is due to the expanding prevalence of infectious diseases, rising investments in healthcare infrastructure, and growing demand for personalized medicine. Moreover, China’s PCR Technology Market held the largest market revenue share, and the Indian PCR Technology Market was the fastest-growing market in the Asia-Pacific region.

Polymerase Chain Reaction (PCR) Technology Key Market Players & Competitive Insights

Leading market players are investing largely in the research and development in order to expand their product lines, which will help the PCR Technology Market grow even more. Market participants are also undertaking different strategic activities to spread their global footprint, with important market developments including contractual agreements, new product launches, mergers and acquisitions, larger investments, and collaboration with other organizations. To expand and sustain itself in a more competitive and rising market climate, the Polymerase Chain Reaction (PCR) Technology industry must offer cost-effective items.

Manufacturing to minimize the operational costs is one of the key business tactics used by the manufacturers in the global Polymerase Chain Reaction (PCR) Technology industry to benefit the clients and increase the market sector. The Polymerase Chain Reaction (PCR) Technology industry has delivered some of the most significant advantages to healthcare. Primary players in the PCR Technology Market, including F. Hoffmann-La Roche Ltd, Bio-Rad Laboratories, Inc., Agilent Technologies, Inc., bioMérieux, S.A., Thermo Fisher Scientific Inc., Enzo Life Science, Inc., Abbott Laboratories, Becton, Dickinson and Company, Takara Bio Inc., and Danaher Corporation, and others, are endeavoring to raise the market demand by investing in the research and development operations.

Bio-Rad Laboratories, Inc. is a global manufacturer and distributor of life science research and clinical diagnostic products. Established in 1952 by David and Alice Schwartz, the company has grown into a prominent player in the biotechnology industry, known for its innovative technologies and high-quality products. Bio-Rad's product portfolio spans a wider range of applications, including genomics, proteomics, cell biology, and clinical diagnostics, catering to researchers, healthcare professionals, and biopharmaceutical companies worldwide. The company is recognized for its expertise in areas such as PCR (Polymerase Chain Reaction), electrophoresis, imaging, and quality control systems for laboratories. In May 2022, Bio-Rad Laboratories, Inc. introduced its CFX Duet Real-time PCR system in selected countries accepting the CE Mark. The system supports researchers in developing singleplex and duplex quantitative PCR (qPCR) assays.

Danaher Corporation is a multinational conglomerate known for its diverse portfolio of life sciences, diagnostics, and environmental businesses. Founded in 1969 and headquartered in Washington, D.C., Danaher has grown into a global leader in science and technology-driven solutions. The company operates through various subsidiaries, including Beckman Coulter, Cepheid, and Leica Microsystems, offering a wide range of products and services for medical diagnostics, life sciences research, water quality analysis, and industrial applications. Danaher has consistently demonstrated strong financial performance and strategic acquisitions, solidifying its position as a key player in the healthcare and environmental sectors. Through its commitment to advancing science and improving lives, Danaher continues to drive growth and make a meaningful impact on global health and sustainability. In January 2022, Danaher Corporation declared that Health Canada issued Cepheid a medical device license for the Xpert Xpress SARS-CoV-2/Flu/RSV.

Key Companies in the PCR Technology Market include

• Hoffmann-La Roche Ltd


• Bio-Rad Laboratories, Inc.


• Thermo Fisher Scientific Inc.


• Agilent Technologies, Inc.


• bioMérieux, S.A.


• Enzo Life Science, Inc.


• Abbott Laboratories


• Takara Bio Inc.


• Becton


• Dickinson and Company


• Danaher Corporation

Polymerase Chain Reaction (PCR) Technology Industry Developments

November 2022: Cepheid launched Xpert Xpress MVP, a multiplexed PCR test that detects DNA from organisms related to three distinct conditions, vulvovaginal candidiasis, bacterial vaginosis (BV), and trichomoniasis, from a single sample, helping in more accurate diagnosis and antibiotic treatment regimens.

March 2021: Agilent Technologies Inc. launched a real-time reverse transcription PCR-based diagnostic kit for the detection of SARS-C0V-2 RNA.

October 2021: Provider of scientific instruments, reagents & consumables, Thermo Fisher Scientific launched the Applied Biosystem QuantStudio Absolute Q-Digital PCR system, which is the first fully integrated digital PCR system fabricated to offer highly accurate and consistent results in the genetic analysis and research in 90 minutes.

PCR Technology Market Segmentation

Polymerase Chain Reaction (PCR) Technology Product Outlook

• Reagents & Consumables


• Instruments


• Software & services

Polymerase Chain Reaction (PCR) Technology Technique Outlook

• Conventional PCR


• Real-Time PCR


• Digital PCR


• Reverse Transcription PCR


• Hot-start PCR


• Multiplex PCR


• Others

Polymerase Chain Reaction (PCR) Technology End User Outlook

• Hospitals and Diagnostic Centers


• Healthcare Industry


• Academia & Government Organizations


• Pharma-Biotech Companies


• Applied Industries


• Others

Polymerase Chain Reaction (PCR) Technology Regional Outlook

• 
  
  Middle East
  
  


• 
  
  Africa
  
  


• 
  
  Latin America
  
  

Report Attribute/Metric	Details
Market Size 2024	16.21 (USD Billion)
Market Size 2025	17.54 (USD Billion)
Market Size 2034	35.67 (USD Billion)
Compound Annual Growth Rate (CAGR)	8.20 % (2025 - 2034)
Report Coverage	Revenue Forecast, Competitive Landscape, Growth Factors, and Trends
Base Year	2024
Market Forecast Period	2025 - 2034
Historical Data	2020 - 2024
Report Coverage	Revenue Forecast, The Market Competitive Landscape, Growth Factors, and Trends
Segments Covered	Product, Technique, End User, and Region
Geographies Covered	North America, Europe, Asia Pacific, and the Rest of the World
Countries Covered	The US, Canada, Germany, France, UK, Italy, Spain, China, India, Australia, Japan, South Korea, and Brazil
Key Companies Profiled	F. Hoffmann-La Roche Ltd, Bio-Rad Laboratories, Inc., Thermo Fisher Scientific Inc., Agilent Technologies, Inc., bioMérieux, S.A., Enzo Life Science, Inc., Abbott Laboratories, Takara Bio Inc., Becton, Dickinson and Company, and Danaher Corporation
Key Market Opportunities	·       Expansion into point-of-care (POC) and decentralized testing settings.
Key Market Dynamics	·       Continuous evolution of the technique itself leads to the development of novel variants and enhancements.